Feature | February 27, 2013

Oncology Information Systems' Reporting and Alerts Leave Providers Wanting More

As meaningful use and ACOs pick up steam, oncology providers contend with regulatory pressures with or without help from their vendors

Oncology Information Management Systems KLAS Meaningful Use Reports Alert

February 27, 2013 — Alerts and reporting are two of the most challenging aspects of medical oncology, in addition to being the tools providers are least happy with overall. This is according to a new report from KLAS titled Oncology 2012: Pulling the Curtain Back.

Study findings reveal that oncology information system vendors struggle with alerts. Specifically, Epic, Varian and Elekta seem to perform below average. Reporting is also an area for improvement. Providers report that Varian and Elekta's canned reports are not robust enough to meet their needs, and the customized reports are difficult to use. Epic's customized reports are not as user friendly as providers would like them to be.

Meaningful use (MU) is another hot button for providers. The vast majority of oncology providers interviewed indicate that they are planning to attest for MU, but according to the report, vendors differ in their ability to partner with providers in that effort. Altos and BMSi are the best reported MU partners because they are more hands on and appear to be more focused on customer needs.

Though Varian is one of the dominant players in the oncology IT market, the report indicates that they are not the best MU partner. The MU version of Varian ARIA did not come out on the promised timeline, and some providers report that Varian seems out of touch with customers. Additionally, Epic is identified as a vendor that could improve due to the fact that the system is not designed for all the needs of oncology providers.

With MU Stage 2 bearing down, patient portals are also identified as an important consideration for oncology providers. Only 30 percent of those surveyed said they are currently using a patient portal, and many still need to make that decision.

"Most of the Epic and Altos customers in the study said they are using patient portals; however, we spoke with only a small number of those customers," said Monique Rasband, oncology research director and author of the report. "The majority of Elekta and Varian customers have not yet adopted a portal. Most Varian and Elekta customers said they are looking to their current oncology IT vendor to supply a portal, in spite of most portals being rudimentary at this point."

This study includes ratings on medical and radiation oncology IS vendors. Vendors rated in radiation oncology are BMSi, Elekta and Varian. Vendors rated in medical oncology are Altos (early data), Elekta, Epic, IntrinsiQ and Varian. To learn more about the oncology IS market and the vendors in this study, providers and vendors can review the full report Oncology IT: Pulling the Curtain Back. This report is available to healthcare providers at a significant discount.

For more information: www.KLASresearch.com/KLASreports

Related Content

News | Radiation Therapy | September 27, 2016
Survival rates for elderly patients receiving stereotactic body radiation therapy (SBRT) for early-stage non-small cell...
prostate cancer, hypofractionated radiationt therapy, accelerated RT, side effects, treatment time, ASTRO 2016, NRG Oncology/RTOG 0415
News | Prostate Cancer | September 27, 2016
September 27, 2016 — For men with early stage, low-risk...
stereotactic radiosurgery, SRS, standard of care, resected brain metastases, ASTRO 2016
News | Radiation Therapy | September 27, 2016
For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in...
Elekta, Radiating Hope volunteer organization, ASTRO 2016, partnership
News | Radiation Therapy | September 27, 2016
Elekta announced that it has expanded its partnership with Radiating Hope, a volunteer organization that provides...
prostate cancer, novel intrinsic subtypes, study, ASTRO 2016
News | Prostate Cancer | September 26, 2016
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes...
Mevion, RaySearch, ASTRO 2016, collaboration, RayCare OIS, S250i, Hyperscan, Adaptive Aperture
News | Radiation Therapy | September 26, 2016
RaySearch and Mevion Medical Systems are extending their collaboration agreement to support the RayCare oncology...
News | Lung Cancer | September 26, 2016
September 26, 2016 — A new analysis of Veteran’s Affairs Central Cancer Registry records demonstrates a clear positiv
IBA, Philips, adaptive proton therapy planning, ASTRO 2016, collaboration
News | Proton Therapy | September 26, 2016
September 26, 2016 — IBA (Ion Beam Applications S.A.) and Philips announced that they are stepping up their combined
brain metastases, stereotactic radiosurgery, SRS, local recurrence, ASTRO 2016 study
News | Radiation Therapy | September 26, 2016
Stereotactic radiosurgery (SRS) for brain metastases decreases the likelihood of local recurrence but shows no positive...
Overlay Init